Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-07-31

Clinical Trial Update: A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the performance of a glucose blinding protein-based continuous glucose monitor (GBP CGM) in individuals with Type 1 diabetes mellitus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: University of Virginia | Conditions: Type 1 Diabetes Mellitus | Phase 2 | Status: COMPLETED | Results posted: 2015-07-31